Publications by authors named "Sohail Rahmany"
Goals: We assessed clinical outcomes over 6 months in an integrated analysis of inflammatory bowel disease (IBD) patients switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX).
Background: Real-world data from large multinational IBD patient populations treated with SC IFX are lacking.
Study: This individual participant data meta-analysis combined anonymized data from 3 real-world cohorts and evaluated clinical remission [Crohn's disease (CD): Harvey-Bradshaw Index (HBI)/modified HBI (mHBI) <5; ulcerative colitis (UC): Simple Clinical Colitis Activity Index (SCCAI)/partial Mayo score (PMS) <3], disease activity (HBI/mHBI/SCCAI/PMS), treatment persistence, pharmacokinetics, immunogenicity, biomarkers [fecal calprotectin (FCP); C-reactive protein (CRP)], and reasons for discontinuation.
Background: Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies. We aimed to describe the treatment population, effectiveness and safety of filgotinib in a real-world cohort of patients with UC.
Methods: A retrospective observational cohort evaluation was conducted across nine UK inflammatory bowel disease centres.
Article Synopsis
- The study focused on patient experiences and clinical outcomes when transitioning from the reference adalimumab to its biosimilar SB5 among Crohn's disease patients.*
- Conducted as a phase IV single-centre trial, it involved 112 participants who were monitored for baseline clinical status, treatment satisfaction, and adverse events during the switch between the two medications.*
- Results showed comparable maintenance of clinical status (81.8% for adalimumab vs. 79.5% for SB5) and similar patient-reported outcomes, although patients reported more injection pain with SB5; overall, the transition did not negatively impact treatment effectiveness.*
Introduction: Patients with suspected inflammatory bowel disease (IBD) referred from primary care often face diagnostic and treatment delays. This study aimed to compare a novel direct-access IBD endoscopy pathway with the traditional care model.
Method: Single centre real-world study analysing primary care referrals with suspected IBD.
Background And Aims: Subcutaneous [SC] vedolizumab presents the opportunity for inflammatory bowel disease [IBD] patients to manage their treatment at home. There are currently no data on the process of transitioning patients established on intravenous [IV] to SC vedolizumab as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC, at 12 weeks following the transition.
View Article and Find Full Text PDF